Results 151 to 160 of about 83,505 (263)
The different face of skin‐rash induced by brentuximab vedotin
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri +11 more
wiley +1 more source
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes. [PDF]
Cholack GA +16 more
europepmc +1 more source
Emerging Techniques in Minimally Invasive Surgery in Hematologic Malignancies
ABSTRACT Hematologic malignancies represent the most common cancers in children. While the mainstays of treatment are chemotherapy and potentially hematopoietic stem cell transplant, minimally invasive surgery (MIS) has a role in the diagnosis and management of complications related both to disease and therapy as well as common pediatric surgical ...
Alejandro Chara +3 more
wiley +1 more source
Delayed Autoimmune Hemolytic Anemia After Remission in Non-Hodgkin Lymphoma. [PDF]
Azinge N +5 more
europepmc +1 more source
[Malignant lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma)].
openaire +2 more sources
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo +2 more
wiley +1 more source
Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma. [PDF]
Falade AS +23 more
europepmc +1 more source
ABSTRACT Cardiac dysfunction is a major morbidity among survivors of adolescent and young adult (AYA) lymphoma. Although high mortality after cardiovascular disease (CVD) diagnosis has been shown in other cancer survivor populations, this has not been investigated in a diverse population of survivors of AYA lymphoma.
Karan Gowda +17 more
wiley +1 more source
Correction: CAR-T cell therapy in non-Hodgkin lymphoma: a clinical trial landscape review. [PDF]
Wu J, Liao Y, Wang W, Zhang X.
europepmc +1 more source
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi +15 more
wiley +1 more source

